Wall Street Zen Downgrades Nanovibronix (NASDAQ:FEED) to Sell

Nanovibronix (NASDAQ:FEED) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings began coverage on shares of Nanovibronix in a research note on Tuesday, January 27th. They issued a “sell (e+)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Nanovibronix Price Performance

Shares of NASDAQ:FEED opened at $2.01 on Friday. Nanovibronix has a 52-week low of $0.99 and a 52-week high of $162.50. The company has a market capitalization of $2.19 million, a price-to-earnings ratio of -0.05 and a beta of 2.26.

Insider Buying and Selling

In other Nanovibronix news, major shareholder Christian Michael Glibert bought 240,000 shares of the stock in a transaction on Wednesday, January 14th. The stock was purchased at an average price of $2.67 per share, for a total transaction of $640,800.00. Following the completion of the purchase, the insider directly owned 240,000 shares in the company, valued at approximately $640,800. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.40% of the stock is currently owned by corporate insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.